Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTION-NSCLC: MRD-Guided Adjuvant Therapy in Stage I NSCLC
NCT06709274Not yet recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Nov 2024
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of osimertinib, alectinib and toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Disease-Free Survival Rate at 3 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06709274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709274.